{
  "version": "2025-10-10",
  "model": "llama-3.1-8b-instant",
  "apiBase": "https://my-chat-agent.tonyabdelmalak.workers.dev/chat",
  "stream": false,
  "modes": ["emotional-assessment", "hiv-product-knowledge", "sales-simulation"],
  "analyticsEndpoint": "https://my-chat-agent.tonyabdelmalak.workers.dev/coach-metrics",
  "scenarios": [
    {
      "id": "prep_im_decile3_lowshare",
      "label": "Dr. Harper - Internal Medicine, Decile 3 (PrEP: low Descovy share)",
      "personaKey": "im_decile3",
      "therapeuticArea": "HIV - PrEP",
      "background": "Established Internal Medicine MD, Decile 3. Descovy TRx share 32%, NBRx share 20%. Claims practice has few PrEP patients. Office reports HCP only prescribes Descovy when patients request it. Clinic seeing increased STI testing in young MSM population. Team prefers Descovy but sales remain stagnant.",
      "goal": "Create urgency around steady flow of young MSM seeking STI testing and gain commitment to prescribe Descovy for PrEP when appropriate."
    },
    {
      "id": "prep_np_decile10_highshare",
      "label": "Alex Nguyen, NP - Decile 10 (PrEP: high Descovy share, expand)",
      "personaKey": "np_decile10",
      "therapeuticArea": "HIV - PrEP",
      "background": "Busy NP, Decile 10. Descovy TRx share 59%, NBRx 64%. Total unrestricted access 75%; share in unrestricted plans 64%. Lacks staff/resources to manage prior auths so is not prescribing broadly, though agrees Descovy is preferred.",
      "goal": "Gain commitment to prescribe broadly for appropriate naive patients and revisit patients on generics who have unrestricted Descovy access."
    },
    {
      "id": "tx_pa_toptier_switch_slowdown",
      "label": "Samantha Lee, PA - Top HIV clinic (Tx: switches slowed)",
      "personaKey": "pa_hiv_top",
      "therapeuticArea": "HIV - Treatment",
      "background": "PA in busy HIV clinic >10 years. Early in launch actively switched many to Biktarvy. Past 13 weeks: only 1-2 switches. Current Biktarvy share 50%; DVY/TVY 12%; Triumeq 9%. States remaining patients are reluctant and are doing fine on current regimens.",
      "goal": "Rebuild confidence in Biktarvy data so HCP can educate patients and identify additional appropriate switch candidates."
    },
    {
      "id": "tx_np_favoring_cab",
      "label": "Jamie Ortiz, NP - 3 years in HIV (Tx: favoring Cabenuva)",
      "personaKey": "np_hiv_newer",
      "therapeuticArea": "HIV - Treatment",
      "background": "Newer NP ~3 years. Uses Biktarvy for naive patients, but Biktarvy share down 10% over 4 months. CAB share 7% and rising. Patients request long-acting injectable; NP accommodates and views CAB as good for highly adherent patients.",
      "goal": "Educate on resistance risk and long-term consequences; align on appropriate patient selection and monitoring."
    },
    {
      "id": "covid_institution_orderset_shift",
      "label": "Dr. Underwood - Hospitalist (COVID: order set shift to Paxlovid)",
      "personaKey": "md_hosp_remdesivir_consistent",
      "therapeuticArea": "COVID",
      "background": "Longstanding prescriber of remdesivir for high-risk progression. Institution changed order sets emphasizing Paxlovid; remdesivir use declined.",
      "goal": "Clarify evidence-based positioning and process pathways to restore appropriate remdesivir use under new order sets."
    },
    {
      "id": "covid_wait_and_see",
      "label": "Dr. Fabiano - Hospitalist (COVID: wait-and-see approach)",
      "personaKey": "md_remdesivir_waitsee",
      "therapeuticArea": "COVID",
      "background": "Consistent remdesivir prescriber for high-risk patients over past 6 months. Recently prefers to wait before initiating therapy.",
      "goal": "Address hesitation with timely-initiation data and define clear triggers to treat."
    },
    {
      "id": "hbv_denials_step_edit",
      "label": "Dr. Smith - Hepatology (HBV: Vemlidy denials / step edit)",
      "personaKey": "hbv_md_denials",
      "therapeuticArea": "HBV",
      "background": "Recognizes benefits of starting Vemlidy in newly diagnosed, treatment-naive patients. Plans frequently denied; step edit required.",
      "goal": "Equip office with access resources and payer-specific pathways to overcome denials and initiate Vemlidy when appropriate."
    },
    {
      "id": "hbv_high_tdf_share_no_shift",
      "label": "Dr. Jones - GI (HBV: high TDF share, slow upgrade)",
      "personaKey": "hbv_md_tdf_high",
      "therapeuticArea": "HBV",
      "background": "High TDF share. HCP agrees to upgrade appropriate patients to Vemlidy but numbers remain flat.",
      "goal": "Convert intent to action using identification lists, safety/renal/bone rationale, and a follow-up plan to track conversions."
    },
    {
      "id": "flu_idn_declining_prebook",
      "label": "IDN Clinical Team - Population Health (Flu: pre-book down)",
      "personaKey": "idn_exec_flu",
      "therapeuticArea": "Influenza Vaccines",
      "background": "IDN reduced pre-book doses for two consecutive seasons: 75k -> 67k -> 58k. Population data show increased flu incidence. Seeking resources to raise immunization rates.",
      "goal": "Present burden of disease and CSL Seqirus programs; propose FY25 campaign plan to increase awareness and vaccination rates."
    },
    {
      "id": "flu_peds_competitor_locked",
      "label": "Pediatrics Office - Practice Manager (Flu: competitor contracted)",
      "personaKey": "peds_office_mgr",
      "therapeuticArea": "Influenza Vaccines",
      "background": "New pediatric account already contracted with competitor for flu supply; vendor supplies other vaccines and has an established relationship.",
      "goal": "Build relationship, map unmet needs, and position CSL Seqirus as year-round resource with a path to future pre-book consideration."
    }
  ]
}
